NCT02229877已完成1 期
A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)0 个研究点目标入组 18 人开始时间: 2014年10月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 主要终点
- Effect of Intragastric pH on gefapixant PK
研究概览
简要总结
The purpose of this study is to: determine the effect of stomach pH on the multiple dose pharmacokinetics (PK) of gefapixant (AF-219); assess the effect of multiple doses of gefapixant on various sensory assessments; and, assess the safety and tolerability of gefapixant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must be informed of the nature of the study and have provided written informed voluntary consent;
- •Able to speak, read, and understand English;
- •Healthy males or females, of any race, between 18 and 55 years of age, inclusive;
- •Body mass index (BMI) >18.5 and <32.0 kg/m2 and weigh 50 - 100 kg;
- •In good general health ;
- •Non-smokers for at least 5 years;
- •If a female of child-bearing potential (i.e., have not undergone a hysterectomy or bilateral oophorectomy) or not post-menopausal (defined as no menses for at least 12 months), agree to use 2 forms of acceptable birth control; or if a male, they and/or their partner of child-bearing potential agree to use 2 forms of acceptable birth control;
排除标准
- •Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease;
- •Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication;
- •Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hay fever during the time of the year that dosing will be taking place;
- •History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton pump inhibitors within 12 months of Screening;
- •Have a positive screening test for Helicobacter pylori;
- •QTcB >450 msec in males or >460 msec in females;
- •Known or suspected hypersensitivity or allergic reaction to any of the components of gefapixant or omeprazole capsules;
- •If female, is pregnant or breast feeding, or has a positive pregnancy test pre dose;
- •Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of the first dose of study drug;
- •Chronic use of any systemic medications; use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications including antacids, high dose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug;
- •Past or current history or evidence of drug or alcohol abuse, use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or pre dose;
- •Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration;
- •Positive urine cotinine test at Screening or Day 1 pre dose;
- •Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody;
- •Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication;
- •Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication
研究组 & 干预措施
Gefapixant + Omeprazole
Experimental
Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days
- Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days
干预措施: Omeprazole (Drug)
Gefapixant + Omeprazole
Experimental
Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days
- Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days
干预措施: Gefapixant (Drug)
结局指标
主要结局
Effect of Intragastric pH on gefapixant PK
时间窗: At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose
Analysis of variance (ANOVA) will be performed on log normal-transformed Cmax and AUC0-t values to determine the extent of a drug interaction, if any, of omeprazole on the plasma gefapixant PK parameters. These analyses will be conducted for both fed and fasted conditions and the 50 mg and 150 mg treatments.
次要结局
- Effect of Fasting on gefapixant PK(At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose)
研究者
相似试验
已完成
1 期
A Study of Baricitinib and Omeprazole in Healthy ParticipantsHealthy VolunteersNCT01925144Eli Lilly and Company30
已完成
1 期
A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy PeopleOsteoporosisNCT00508534GlaxoSmithKline13
已完成
1 期
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast CancerNeoplasms, BreastNCT00849329GlaxoSmithKline12
已完成
1 期
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333HCV InfectionNCT00768690Abbott45
已完成
1 期
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis CHCV InfectionNCT00890318Abbott32